Literature DB >> 8447300

Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans.

M G Suranyi1, A Guasch, B M Hall, B D Myers.   

Abstract

To investigate the possible role of cytokines in the mediation of glomerular injury in the nephrotic syndrome, the levels of interleukin (IL)-1 beta, IL-2, interferon (IFN)-alpha, IFN-gamma, and tumor necrosis factor-alpha (TNF-alpha) were measured in patients with primary nephrotic syndrome. These patients had minimal change nephropathy (MCN), focal and segmental glomerulosclerosis (FSGS), or membranous nephropathy (MN) on biopsy. Cytokine levels were assessed by immunoradiometric assays, and specimens consisted of plasma, urine, and the culture supernate of mitogen-stimulated peripheral blood mononuclear cells (PBMC). Only TNF-alpha was found to be significantly elevated, in the plasma and urine of patients with FSGS and MN, above that found in healthy control subjects and patients with MCN. The elevation of TNF-alpha could not be shown to correlate with the length or severity of the nephrotic syndrome or with loss of body mass. IL-1 beta, IL-2, IFN-alpha, and IFN-gamma levels were not elevated. In culture, mitogen-stimulated PBMC from all three groups of nephrotic subjects released an excess of TNF-alpha compared with controls, a response not consistently observed for the other cytokines measured. The findings of this survey of cytokine levels in nephrotic patients support the possibility that TNF-alpha may play a pathogenic role in the induction or maintenance of glomerular barrier dysfunction in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447300     DOI: 10.1016/s0272-6386(12)80742-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  56 in total

1.  Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis.

Authors:  Shuichi Ito; Akiko Tsutsumi; Tomonori Harada; Aya Inaba; Shuichiro Fujinaga; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2010-06-09       Impact factor: 3.714

2.  Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association.

Authors:  Masaru Togashi; Hideki Wakui; Koya Kodama; Yoshihiro Kameoka; Atsushi Komatsuda; Takashi Nimura; Ryo Ichinohasama; Ken-Ichi Sawada
Journal:  Clin Exp Nephrol       Date:  2010-02-23       Impact factor: 2.801

3.  High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Jolanta Tobolczyk; Edyta Tenderenda
Journal:  Pediatr Nephrol       Date:  2006-11-18       Impact factor: 3.714

4.  TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Authors:  Martin Bitzan; Sima Babayeva; Anil Vasudevan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2012-04-27       Impact factor: 3.714

5.  T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

Authors:  Carlos Araya; Leila Diaz; Clive Wasserfall; Mark Atkinson; Wei Mu; Richard Johnson; Eduardo Garin
Journal:  Pediatr Nephrol       Date:  2009-06-03       Impact factor: 3.714

Review 6.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

7.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

8.  A new mouse model of hemorrhagic shock-induced acute kidney injury.

Authors:  Lei Wang; Jiangping Song; Jacentha Buggs; Jin Wei; Shaohui Wang; Jie Zhang; Gensheng Zhang; Yan Lu; Kay-Pong Yip; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2016-11-09

9.  Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production.

Authors:  S P Chen; W Cheung; C K Heng; S C Jordan; H K Yap
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.